# Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/clinical-responses-to-egfr-tyrosine-kinase-inhibitor-retreatment-in-non-small/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Satoshi Watanabe,Junta Tanaka,Takeshi Ota,Rie Kondo,Hiroshi Tanaka,Hiroshi Kagamu,Kosuke Ichikawa,Jun Koshio,Junko Baba,Takao Miyabayashi,Ichiei Narita,Hirohisa Yoshizawa |
| Citations | 394 |
| DOI | 10.1186/1471-2407-11-1 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://bmccancer.biomedcentral.com/counter/pdf/10.1186/1471-2407-11-1 |
| OpenAlex ID | https://openalex.org/W2151881986 |
| PMID | 21194487 |
| Type | article |
| Year | 2011 |

## Paper authors

- [Ichiei Narita](https://scholariq.org/researchers/ichiei-narita/)

## Paper journal

- [BMC Cancer](https://scholariq.org/journals/bmc-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.